Vinorelbine 50mg/5mL
Product Overview
| Generic Name | Vinorelbine 50mg/5mL |
| Brand Name(s) | Navelbine |
| Category | Antineoplastic / Cancer |
| Form | Injection/IV solution |
| Strength | 50mg/5mL |
| Therapeutic Class | Vinca alkaloid analogue, antineoplastic agent |
| ATC Code | L01CA04 |
Manufacturing & Regulatory
| Manufacturer | Pierre Fabre Pharma, Flroencia |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Not publicly disclosed |
| COFEPRIS | Pending |
| Free Sale Certificate | Available from supplier on request |
Logistics & Export
| MOQ | 5 |
| Shelf Life | 24 Months |
| Storage | Store at 20–25 °C |
| Incoterms | EXW/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request, not publicly posted |
| CTD Summary (PDF) | CTD available to regulators; summary available to qualified partners |
Special Notes
Vinorelbine is indicated for the treatment of non-small-cell lung cancer (NSCLC) and in some jurisdictions for metastatic breast cancer.